January 27, 2025 — A new paper this morning in Nature Medicine tells us that interrupting liver disease in obesity is possible with metabolic surgery. More specifically, in an observational study of patients with obesity and cirrhosis due to MASH, Ali Aminian and colleagues found a 72% lower risk of major complications from liver disease in patients who received […]
November 14, 2024 — In the New England Journal of Medicine yesterday, detailed results of a three-year study showed that tirzepatide was 99% effective in preventing diabetes in people with prediabetes and obesity. This was a placebo-controlled trial. Every person in the study, whether they received tirzepatide or not, received regular lifestyle counseling. Compared to the control group getting […]
July 6, 2024 — We’ve been hearing quite a lot about this on many levels. For years now, obesity thought leaders and even the public have had an increasingly sour relationship with BMI. It’s been misused, abused, detested, and even accused of racism. Yes, the love is gone. On Friday, the European Association for the Study of Obesity (EASO) […]
August 28, 2023 — On Friday, NEJM published impressive results in an RCT of semaglutide for treating patients who have obesity and heart failure with preserved ejection fraction (HFpEF). The treatment enabled these people to function better, feel better, and suffer half as many serious adverse events. These are important benefits for people with a very difficult condition. But […]
